JW1601, an oral atopy treatment candidate that was licensed by JW Pharmaceutical to Ballerup, Denmark-based Leo Pharma began Phase 2 clinical trials, the Korean company said Wednesday.
JW Holdings signed a memorandum of understanding with light emitting diode (LED) maker IL Science in a move to target global alopecia market, the company said Wednesday.
Korea JoongAng Daily Sitemap
